# Edgewood Oncology

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/edgewood-oncology

- Industry: Biotechnology
- Headquarters: Brookline, US
- Website: www.edgewoodoncology.com/
- Total disclosed funding: $10M
- Latest round: Series A (Mar 25, 2024)
- Investors on record: 1

## About

Based in Massachusetts, US, Edgewood Oncology, Inc. operates as a biotechnology company that engages in the development of medication for individuals with solid tumors. In March 2024, the firm raised USD 20 million in series A funding led by investor Alta Partners. The firm as of March 2024, is led by its CEO, David N. Cook, and CMO, Zung Thai.

The company engages in the development of treatments for patients with hematologic malignancies and genetically-defined solid tumors. Edgewood’s flagship product, BTX-A51, is a novel small-molecule multi-kinase inhibitor. BTX-A51 targets master regulators of cancer, including CK1a, CDK7, and CDK9, to activate programmed cell death, demonstrating promising clinical activity with a favorable safety profile. This mechanism of action holds promise in hematologic malignancies and genetically-defined solid tumors, such as GATA3-mutant breast cancer and Liposarcoma.

The company plans to utilize the March 2024 funding to progress BTX-A51 in individuals suffering from genetically-defined solid tumors and hematologic malignancies.

## Funding rounds

- Series A, Mar 25, 2024, $10M — Alta Partners

## Investors

- Alta Partners (https://capitalatlas.ai/funds/alta-partners) — Series A